Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88899 | 0.71 | ALOX15 (0.56) | ALOX15HSD17B10CA12CA9CYP1A2 | |
| SCHEMBL2087881 | 0.71 | ALOX15 (1.00) | ALOX15HSD17B10CA12CA9CYP1A2 | |
| SCHEMBL31546300 | 0.71 | ALOX15 (1.00) | ALOX15HSD17B10CA12CA9CYP1A2 | |
| SCHEMBL20932667 | 0.71 | ALOX15 (0.56) | ALOX15HSD17B10CA12CA9CYP1A2 | |
| SCHEMBL89023 | 0.71 | ALOX15 (0.56) | ALOX15HSD17B10CA12CA9CYP1A2 | |
| SCHEMBL12903036 | 0.69 | ALDH1A1 (0.33) | ALOX15HSD17B10PNMTGAA | |
| SCHEMBL19939638 | 0.69 | ALOX15 (0.58) | ALOX15HSD17B10CYP1A2PNMTCD44 | |
| SCHEMBL4574632 | 0.68 | CYP1A2 (0.50) | ALOX15HSD17B10CYP1A2MAOBCYP2A6 | |
| SCHEMBL29795304 | 0.68 | CYP1A2 (0.50) | ALOX15HSD17B10CYP1A2MAOBCYP2A6 | |
| SCHEMBL14061414 | 0.67 | CA12 (0.56) | ALOX15HSD17B10CA12CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-10035789-B2 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-10000496-B2 | Compositions useful for treating disorders related to kit and PDGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-02-01 | — | — | US | disclosed |
| US-20180022731-A1 | 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170022206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDFGR | BLUEPRINT MEDICINES CORPORATION | 2017-01-26 | — | — | US | disclosed |
| US-9434700-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 2016-09-06 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9200002-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150111887-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2015-04-23 | — | — | US | disclosed |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
| US-8188080-B2 | VHR protein tyrosine phosphatase inhibitors, compositions and methods of use | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090105254-A1 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035789-B2 | Compounds useful for treating disorders related to RET | RET, EYA2, HRAS | ALOX15 4275/4885HSD17B10 1700/4885CA12 4575/4885 |
| US-20090105254-A1 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | PTPRR, PTPRS, PTPRCAP | ALOX15 4656/4885HSD17B10 3457/4885CA12 2523/4885 |
| US-20170022206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDFGR | KIT, PDGFRA, PDGFRB | ALOX15 3353/4885HSD17B10 2645/4885CA12 4853/4885 |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | ALOX15 3075/4885HSD17B10 1508/4885CA12 4826/4885 |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | RET, EYA2, HRAS | ALOX15 4275/4885HSD17B10 1700/4885CA12 4575/4885 |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | ALOX15 3075/4885HSD17B10 1508/4885CA12 4826/4885 |
| US-20150111887-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | ALOX15 4391/4885HSD17B10 1575/4885CA12 4449/4885 |
| US-10000496-B2 | Compositions useful for treating disorders related to kit and PDGFR | KIT, PDGFRA, PDGFRB | ALOX15 3817/4885HSD17B10 2463/4885CA12 4536/4885 |
| US-20180022732-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | RET, EYA2, HRAS | ALOX15 4275/4885HSD17B10 1700/4885CA12 4575/4885 |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | ALOX15 2595/4885HSD17B10 2863/4885CA12 4348/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | ALOX15 2978/4885HSD17B10 1676/4885CA12 2758/4885 |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | ALOX15 2595/4885HSD17B10 2863/4885CA12 4348/4885 |
| US-20180022731-A1 | 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS | RET, MECP2, RB1 | ALOX15 4746/4885HSD17B10 4386/4885CA12 4850/4885 |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | KIT, APC, MSH2 | ALOX15 4391/4885HSD17B10 1575/4885CA12 4449/4885 |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | ALOX15 4391/4885HSD17B10 1575/4885CA12 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.